Dihydroergotamine Mesylate Spray
Product Images NDC 24201-463

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate (NDC 24201-463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Chemstruct)

Chemical structure of dihydroergotamine mesylate with molecular formula C33H37N5O5•CH4O3S and molecular weight 679.78, showing detailed molecular bonding and arrangement.*

FDA Label Image

Figure1.jpg (Figure1 Updated)

A line graph titled 'Estimated Probability of a Patient Responding During the Four Hours Following a Single 2 mg Dose of Dihydroergotamine mesylate nasal spray as a function of the time elapsed since initiation of treatment.' The x-axis represents time in hours from the first dose (0 to 4 hours), and the y-axis shows the estimated probability of response to study medication as a percentage (0% to 100%). Two lines compare Dihydroergotamine mesylate and placebo responses over time, with Dihydroergotamine mesylate showing a higher probability of patient response compared to placebo throughout the 4-hour period.*

FDA Label Image

Figure2.jpg (Figure2 Update)

A line graph showing the estimated probability (%) of patients responding to Dihydroergotamine Mesylate nasal spray versus placebo over four hours following dosing. The graph plots response probability on the y-axis from 0 to 100% and time from first dose in hours on the x-axis from 0 to 4 hours. Dihydroergotamine Mesylate shows a higher increasing response rate over time compared to placebo in studies 3 and 4 with sample sizes of 97 and 100 respectively.*

FDA Label Image

Figure3.jpg (Figure3 Update)

A line graph illustrating the estimated probability of patients using additional treatments for migraine over 24 hours after receiving either 2 mg of dihydroergotamine mesylate nasal spray or placebo. The x-axis represents hours after first spray (0-24), and the y-axis shows estimated probability of analgesic use (0%-100%). Two curves are shown: one for dihydroergotamine mesylate and one for placebo, with placebo line trending higher in analgesic use over time.*

FDA Label Image

4mg-ml-carton.jpg (Multi Pack Carton)

Dihydroergotamine Mesylate Nasal Spray 4 mg/mL carton from Hikma Pharmaceuticals USA Inc., containing 8 x 1 mL vials. The label clearly states 'For nasal use only, not for injection' and includes the NDC 24201-463-08. The packaging features the Leucadia logo and provides ingredient and usage information, emphasizing Rx only status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.